Fennec Pharmaceuticals Net Income
| FENC Stock | USD 8.68 0.26 3.09% |
As of the 18th of February 2026, Fennec Pharmaceuticals shows the Downside Deviation of 2.84, coefficient of variation of 1617.51, and Mean Deviation of 2.11. Fennec Pharmaceuticals technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Fennec Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 6.7221 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -392.4 K | -412 K | |
| Net Loss | -21.3 M | -20.3 M | |
| Net Loss | -392.4 K | -412 K | |
| Net Loss | (0.01) | (0.02) | |
| Net Income Per E B T | 5.53 | 5.80 |
Fennec | Net Income | Build AI portfolio with Fennec Stock |
Analyzing Fennec Pharmaceuticals's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Fennec Pharmaceuticals's current valuation and future prospects.
Latest Fennec Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Fennec Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Fennec Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Fennec Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Fennec Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Fennec Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (436 K) | 10 Years Trend |
|
Net Income |
| Timeline |
Fennec Net Income Regression Statistics
| Arithmetic Mean | (6,506,499) | |
| Coefficient Of Variation | (124.54) | |
| Mean Deviation | 6,820,031 | |
| Median | (2,789,000) | |
| Standard Deviation | 8,103,505 | |
| Sample Variance | 65.7T | |
| Range | 27.5M | |
| R-Value | (0.39) | |
| Mean Square Error | 59.4T | |
| R-Squared | 0.15 | |
| Significance | 0.12 | |
| Slope | (625,486) | |
| Total Sum of Squares | 1050.7T |
Fennec Net Income History
Other Fundumenentals of Fennec Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Fennec Pharmaceuticals Net Income component correlations
Fennec Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Fennec Pharmaceuticals is extremely important. It helps to project a fair market value of Fennec Stock properly, considering its historical fundamentals such as Net Income. Since Fennec Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Fennec Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Fennec Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Fennec diversify its offerings? Factors like these will boost the valuation of Fennec Pharmaceuticals. Market participants price Fennec higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Fennec Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.26) | Revenue Per Share | Quarterly Revenue Growth 0.787 | Return On Assets | Return On Equity |
Understanding Fennec Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Fennec's accounting equity. The concept of intrinsic value - what Fennec Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Fennec Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Fennec Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fennec Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Fennec Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Fennec Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Fennec Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Fennec Pharmaceuticals.
| 11/20/2025 |
| 02/18/2026 |
If you would invest 0.00 in Fennec Pharmaceuticals on November 20, 2025 and sell it all today you would earn a total of 0.00 from holding Fennec Pharmaceuticals or generate 0.0% return on investment in Fennec Pharmaceuticals over 90 days. Fennec Pharmaceuticals is related to or competes with Eupraxia Pharmaceuticals, Aardvark Therapeutics, Cartesian Therapeutics, Prelude Therapeutics, Caribou Biosciences, Avalo Therapeutics, and Enanta Pharmaceuticals. Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company More
Fennec Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Fennec Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Fennec Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.84 | |||
| Information Ratio | 0.0436 | |||
| Maximum Drawdown | 17.84 | |||
| Value At Risk | (4.94) | |||
| Potential Upside | 4.86 |
Fennec Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Fennec Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Fennec Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Fennec Pharmaceuticals historical prices to predict the future Fennec Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0564 | |||
| Jensen Alpha | 0.1599 | |||
| Total Risk Alpha | 0.0124 | |||
| Sortino Ratio | 0.0448 | |||
| Treynor Ratio | 0.6989 |
Fennec Pharmaceuticals February 18, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0564 | |||
| Market Risk Adjusted Performance | 0.7089 | |||
| Mean Deviation | 2.11 | |||
| Semi Deviation | 2.67 | |||
| Downside Deviation | 2.84 | |||
| Coefficient Of Variation | 1617.51 | |||
| Standard Deviation | 2.92 | |||
| Variance | 8.51 | |||
| Information Ratio | 0.0436 | |||
| Jensen Alpha | 0.1599 | |||
| Total Risk Alpha | 0.0124 | |||
| Sortino Ratio | 0.0448 | |||
| Treynor Ratio | 0.6989 | |||
| Maximum Drawdown | 17.84 | |||
| Value At Risk | (4.94) | |||
| Potential Upside | 4.86 | |||
| Downside Variance | 8.08 | |||
| Semi Variance | 7.11 | |||
| Expected Short fall | (2.23) | |||
| Skewness | 0.5917 | |||
| Kurtosis | 2.48 |
Fennec Pharmaceuticals Backtested Returns
Fennec Pharmaceuticals appears to be not too volatile, given 3 months investment horizon. Fennec Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.0819, which denotes the company had a 0.0819 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Fennec Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please utilize Fennec Pharmaceuticals' Coefficient Of Variation of 1617.51, downside deviation of 2.84, and Mean Deviation of 2.11 to check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Fennec Pharmaceuticals holds a performance score of 6. The firm shows a Beta (market volatility) of 0.24, which means not very significant fluctuations relative to the market. As returns on the market increase, Fennec Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Fennec Pharmaceuticals is expected to be smaller as well. Please check Fennec Pharmaceuticals' downside variance, daily balance of power, and the relationship between the maximum drawdown and skewness , to make a quick decision on whether Fennec Pharmaceuticals' price patterns will revert.
Auto-correlation | -0.2 |
Insignificant reverse predictability
Fennec Pharmaceuticals has insignificant reverse predictability. Overlapping area represents the amount of predictability between Fennec Pharmaceuticals time series from 20th of November 2025 to 4th of January 2026 and 4th of January 2026 to 18th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Fennec Pharmaceuticals price movement. The serial correlation of -0.2 indicates that over 20.0% of current Fennec Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.2 | |
| Spearman Rank Test | -0.18 | |
| Residual Average | 0.0 | |
| Price Variance | 0.08 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Fennec Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Fennec Pharmaceuticals reported net income of (436,000). This is 100.13% lower than that of the Biotechnology sector and 100.62% lower than that of the Health Care industry. The net income for all United States stocks is 100.08% higher than that of the company.
Fennec Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fennec Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Fennec Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Fennec Pharmaceuticals by comparing valuation metrics of similar companies.Fennec Pharmaceuticals is currently under evaluation in net income category among its peers.
Fennec Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Fennec Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Fennec Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Fennec Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Fennec Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Fennec Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Fennec Pharmaceuticals' value.| Shares | Gendell Jeffrey L | 2025-06-30 | 139.7 K | Northern Trust Corp | 2025-06-30 | 131.5 K | The Informed Momentum Company (formerly Eam Investors) | 2025-06-30 | 78.7 K | Charles Schwab Investment Management Inc | 2025-06-30 | 61.3 K | Bank Of New York Mellon Corp | 2025-06-30 | 51.8 K | Hartford Financial Management Inc. | 2025-06-30 | 50.6 K | Jane Street Group Llc | 2025-06-30 | 50 K | Susquehanna International Group, Llp | 2025-06-30 | 46.9 K | Citadel Advisors Llc | 2025-06-30 | 46.8 K | Southpoint Capital Advisors Lp | 2025-06-30 | 4.1 M | Solas Capital Management Llc | 2025-06-30 | 2.2 M |
Fennec Fundamentals
| Return On Equity | -10.06 | ||||
| Return On Asset | -0.0539 | ||||
| Profit Margin | (0.18) % | ||||
| Operating Margin | (0.02) % | ||||
| Current Valuation | 260.75 M | ||||
| Shares Outstanding | 34.15 M | ||||
| Shares Owned By Insiders | 13.41 % | ||||
| Shares Owned By Institutions | 50.36 % | ||||
| Number Of Shares Shorted | 769.53 K | ||||
| Price To Earning | (3.82) X | ||||
| Price To Book | 57.93 X | ||||
| Price To Sales | 7.41 X | ||||
| Revenue | 47.54 M | ||||
| Gross Profit | 36.12 M | ||||
| EBITDA | 4.8 M | ||||
| Net Income | (436 K) | ||||
| Cash And Equivalents | 14.91 M | ||||
| Cash Per Share | 0.57 X | ||||
| Total Debt | 19.34 M | ||||
| Debt To Equity | 0.58 % | ||||
| Current Ratio | 5.12 X | ||||
| Book Value Per Share | (0.16) X | ||||
| Cash Flow From Operations | 26.98 M | ||||
| Short Ratio | 6.60 X | ||||
| Earnings Per Share | (0.26) X | ||||
| Target Price | 15.29 | ||||
| Number Of Employees | 32 | ||||
| Beta | 0.77 | ||||
| Market Capitalization | 287.57 M | ||||
| Total Asset | 44.95 M | ||||
| Retained Earnings | (219.68 M) | ||||
| Working Capital | 37.2 M | ||||
| Current Asset | 7.88 M | ||||
| Current Liabilities | 1.97 M | ||||
| Net Asset | 44.95 M |
About Fennec Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fennec Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fennec Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fennec Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Fennec Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fennec Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fennec Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fennec Pharmaceuticals Stock:Check out For information on how to trade Fennec Stock refer to our How to Trade Fennec Stock guide.You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.
Will Biotechnology sector continue expanding? Could Fennec diversify its offerings? Factors like these will boost the valuation of Fennec Pharmaceuticals. Market participants price Fennec higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Fennec Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.26) | Revenue Per Share | Quarterly Revenue Growth 0.787 | Return On Assets | Return On Equity |
Understanding Fennec Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Fennec's accounting equity. The concept of intrinsic value - what Fennec Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Fennec Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Fennec Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fennec Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Fennec Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.